Home » Authors » Karen Carey

Karen Carey

Articles

ARTICLES

TargeGen's Series B Brings In $30M For AMI, Cancer Programs

Jan. 16, 2004

Enanta Raises $12M To Further Macrolide Respiratory Program

Jan. 15, 2004

BioStratum Could Receive $80M Per Antibody In Novo Cancer Deal

Jan. 14, 2004

Acumen, Merck Sign Alzheimer's Disease Pact With $96M Potential

Jan. 14, 2004

Concurrent Raises $15M, Partners With Intel On 'Machine Learning'

Jan. 13, 2004

$19M Private Placement Ranks As Cortex's 'Biggest Financing'

Jan. 12, 2004

ImmunoGen Moving Forward Alone With Cancer Products

Jan. 9, 2004

Forbes Medi-Tech Private Placement Raises $10.75M

Jan. 8, 2004

Diversa Licenses Technologies Through XOMA, Cellectis Deals

Jan. 7, 2004

Repligen's Secretin Fails Autism Phase III; Subgroup Has Promise

Jan. 6, 2004

The new year greeted Repligen Corp. with disappointing data from its Phase III trial of synthetic human secretin in autism. (BioWorld Today)

View All Articles by Karen Carey

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 21, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
LIT-002 is strong candidate for autism and neuropathic pain
BioWorld Science
Researchers from the University of Strasbourg and the Centre National de la Recherche Scientifique (CNRS) have presented data on LIT-002, a nonpeptide oxytocin...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 21, 2026
New biomarker may improve RSV drug screening
BioWorld
Respiratory syncytial virus (RSV) infection is responsible for 3.2 million hospital admissions and about 118,000 deaths in children under 5 years of age. The...